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ABSTRACT
Rodgers, Logan Joseph. MS. The University of Memphis. May 2014. D-Aspartic Acid
As A Nutritional Aid To Increase Serum Testosterone. Major Professor: Dr. Richard
Bloomer.
The purpose of this proposed study was to determine the potential changes in
testosterone (free and total) and estradiol over a four-week intervention period using Daspartic acid (DAA) in men. Twenty-four physically active men, aged 18-39 years, were
randomly assigned to two groups (conditions) using a placebo-controlled, double-blind
design. Baseline values for all hormones were compared to values measured at the end of
two and four weeks of DAA administration, provided at a dosage of 3.12g, compared to
the placebo. Data were analyzed using a 2 (condition) x 3 (time) analysis of variance. No
interaction or main effects were noted for any hormonal variable (p>0.05), with similar
values noted between groups and across time. In conclusion, DAA supplementation for a
28 day period does not increase serum total or free testosterone in young, healthy men.
Moreover, DAA has no impact on serum estradiol concentrations. Future studies may be
designed to investigate the impact of DAA on testosterone and associated health
parameters in a sample of older men and/or those with low testosterone concentrations.
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CHAPTER 1
INTRODUCTION
D-aspartic Acid (DAA) is an endogenous amino acid that has recently become very
popular as a dietary supplement, particularly among athletic men. This is largely fueled
by one human study demonstrating an increase in blood testosterone concentrations
following daily supplementation with DAA over the course of a 12-day period in a group
of 23 men ages 27 to 37 years of age (XVII). While the rise in testosterone is the finding
of most interest to male athletes, DAA may have other health-related implications worth
noting. For example, scientists are beginning to understand the role of DAA within the
nervous system and neuroendocrine system (VI), which may have implications for
enhancing human health. While the mechanisms are not well understood, DAA can be
converted into N-methyl-D- aspartic acid receptors (NMDA receptors), which are a
crucial part of the memory/learning process (VI). Therefore, it is hypothesized that DAA
may play a role in enhancing memory, which could have implications for many
individuals, including those with neurological diseases such as Alzheimer’s (VI, VIII).
DAA been has shown to play a role in synthesis and release of testosterone in
humans (VI). For example, supplementing 3.12g of DAA daily for 12 days was reported
to increase luteinizing hormone (LH) and testosterone by 33% and 42%, respectively
(XVII). In this study, measurements were taken before and after 12 days of

supplementation with DAA. Luteinizing hormone levels increased from baseline values
of 4.2 ± 0.5 mIU/ml to 5.6 ± 0.9 mIU/ml (mean ± SEM). With respect to testosterone,
levels increased from 4.5 ± 0.6 ng/ml to 6.4 ± 0.8 ng/ml (XVII). This noted rise in
testosterone 1) may have been increased further with a longer time course of DAA
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administration and 2) may have implications for improved muscle strength and/or muscle
mass over time. That said, Willoughby and Leutholtz recently reported that the same
dosage of DAA for a 28 day period failed to yield an increase in total or free testosterone
in young (aged 18-23 years) and healthy men (XVIII). It should be noted that DAA
treatment was compared to a placebo and provided in conjunction with a resistance
training program. These findings call into question those of Topo et al (XVII) and
provide an impetus for further study of DAA.
In addition to human intake of DAA, this nutrient has also been reported to play a
role in the synthesis and release of LH and testosterone in animal models. In vivo and in
vitro rat models have been used to show that an increase in testosterone is observed with
a concurrent increase in LH (XIII, XIV, XVII). In addition to an association between
testosterone and LH, in vitro experiments using boar and lizard tissue have reported that
DAA induces an increase in aromatase activity, a key enzyme in the conversion of
testosterone to estrogen. Perhaps due to this increase in aromatase activity, the outcome
of many animal studies involving DAA treatment has been an increase in 17-B-estradiol
levels (I, X, XI), an undesirable effect in men using DAA for health- and performancespecific purposes. However, it is currently unknown as to whether or not DAA use by
human subjects would result in an increase in estrogens, and if so, what amount of DAA
would be needed in order for an increase in estradiol to be noted.
With this information in mind, the present investigation was designed to determine
the effects of DAA administration over a 28 day period on blood levels of total and free
testosterone, as well as estradiol. At the time of study design, the work of Willoughby and
Leutholtz (XVIII) had not yet been published. Therefore, based on the work of Topo and
colleagues (XVII), we hypothesized that total and free testosterone would increase as a
2

result of DAA treatment. Additionally, we maintained a non-directional hypothesis
concerning estradiol levels, as only animal studies using relatively high dosages of DAA
had been conducted with regards to this hormone.
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CHAPTER 2
Design and Methodology
2.1 Overview of Experimental Design
This study was conducted using a placebo controlled, randomized, double-blind, pre-post
intervention design. A total of 24 physically active male subjects, 19-39 years of age
were recruited to participate in this four-week study. Subjects were recruited from The
University of Memphis campus and local community by flyer, snowball
sampling/recruiting, and email messages. Subjects were not current smokers and were
not obese based on the body mass index (BMI <30kg/m2). Subjects did not have
diagnosed metabolic or cardiovascular disease, nor were they taking any medications or
dietary supplements with a potential influence on serum hormone levels. Prior to
participation, all subjects completed a standard health history and dietary
supplement/medication use questionnaire. All procedures were approved by the
Institutional Review Board for Human Subject Research and all subjects provided written
informed consent before being admitted as a subject.
Subjects were randomly assigned in double-blind manner into one of two groups
(conditions), with 12 subjects per group. The groups were: 1) supplement [DAA at 3.12g]
and 2) placebo. The placebo and DAA-containing tablets were similar in appearance and
were provided to subjects in unlabeled bottles. Subjects were instructed to consume three
tablets of their assigned condition each day with a meal, 60 minutes prior to exercise. If
no exercise was performed that day, subjects were to take their three tablets with
breakfast. The treatment period was 28 days, with testing before, after day 14, and after
day 28. Specifically, subjects reported to the lab on days one, 15 (following two weeks of
4

treatment), and 29 (following four weeks of treatment) for resting and fasting blood
samples to be taken. The time of day for reporting to the lab for each subject was
matched for all tests to account for potential changes in hormone levels due to the
circadian rhythm. Upon arrival to the lab, subjects were asked to void and then rested
quietly for 20 minutes before heart rate and blood pressure were measured. Then, a
venous blood sample (~10mL) was obtained from a forearm vein. Blood was allowed to
clot for 30 minutes and then processed in a refrigerated centrifuge to obtain serum. The
serum was stored in multiple aliquots at -70 degrees Celsius. Samples were then analyzed
in duplicate using standard ELISA techniques (assay kits purchased from Calbiotech, Inc,
Spring Valley, CA). The following hormones were analyzed in duplicate on first thaw:
1. Total serum testosterone (Coefficient of variation: 5.4%)
2. Free serum testosterone (Coefficient of variation: 4.8%)
3. Serum estradiol (Coefficient of variation: 7.9%)
On each test day (days 1, 15, and 29), subjects completed a questionnaire that
assessed their subjective feelings regarding the following variables: Alertness, Energy
Level, Vitality, Libido, Workout Effectiveness, Muscle Strength, Muscle Endurance,
Sleep Quality, Mental Outlook and Mood, Physical Appearance. Subjects rated each
variable on a scale from 1-5, with “1” representing the lowest rating and “5” representing
the highest rating. At each time of measurement, subjects were instructed to consider
how they felt in regards to the variables over the past 14 days. Although this was not the
main purpose of the present study, considering the potential impact of testosterone levels
on the above variables, inclusion of this questionnaire seemed appropriate. Diet records
were analyzed for macro- and micro-nutrient content using nutrition analysis software.
Also, subjects were asked not to consume caffeine or alcohol 48 hours prior to each test
5

day.
2.2 Dietary Intake and Physical Activity
Subjects were instructed to maintain their usual diet throughout the study period. Subjects
recorded food and beverage intake during the 48 hours before days 1, 15, and 29.
Records were analyzed total kilocalories, macronutrient and micronutrient intake.
Subjects were asked to maintain their usual physical activity program throughout the
study period. However, subjects did not perform any strenuous exercise during the 48
hours prior to each test day.
2.3 Statistical analysis
Data were analyzed using a 2 (condition) x 3 (time) analysis of variance, with Tukey
post-hoc analysis as needed. Data are presented as mean ± SEM. Statistical significance
was set at P ≤ 0.05.
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CHAPTER 3
Results

3.1 Protocol compliance, deviations and missing data
All 24 subjects successfully completed the four-week study. The following protocol
deviations were noted. Placebo condition: the day 14 visit occurred on day 15 for one
subject and on day 17 for another, due to scheduling conflicts. Furthermore, two subjects
completed the study after 27 days of treatment rather than after 28 days of treatment, due
to scheduling conflicts. Supplement condition: the day 14 visit occurred on day 18 for
one subject, due to scheduling conflicts. The following pieces of data are missing from
the analysis, primarily due to a lack of obtaining the data from the subject. Placebo
condition: questionnaire data at baseline for one subject. Supplement condition: heart
rate/blood pressure and questionnaire data for day 28 for one subject; blood at day 4 visit
for one subject.
3.2 Subject characteristics
Subject characteristics were not different between conditions (p>0.05), as can be viewed
in Table 1. Compliance to capsules was excellent for subjects in both conditions
(placebo: 95.5±2.0%; supplement: 98.2±0.8%). With the exception of vitamin C intake,
which was higher for placebo as compared to supplement (p=0.02), dietary intake was
not different between subjects or across time (p>0.05; Table 2), nor was resting heart rate
or blood pressure (p>0.05; Table 3).
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Table 1. Characteristics of men assigned to placebo or supplement
Variable
Age (years)
Height (cm)
Body Weight (kg)
Body Mass Index (kg∙m-2)
Waist Circumference (cm)
Hip Circumference (cm)
Waist: Hip
Weekly Aerobic Training (hrs)
Aerobic Training History (yrs)
Weekly Anaerobic Training (hrs)
Anaerobic Training History (yrs)
1-Repetition Maximum (kg)

Placebo
(n=12)
24.8±1.5
180.6±1.3
82.4±2.1
25.3±0.8
84.5±1.6
98.5±1.2
0.86±0.01
2.8±0.7
5.0±1.1
4.7±0.4
6.3±0.7
153.0±5.4

Supplement
(n=12)
22.5±0.6
179.0±1.8
81.5±2.4
25.4±0.8
85.2±1.6
98.6±1.9
0.90±0.01
1.8±0.4
5.6±1.2
3.8±0.5
6.0±0.8
136.1±6.4

Values are mean±SEM.
No differences of statistical significance noted (p>0.05).

Table 2. Dietary data of men assigned to placebo or supplement
Variable
Kilocalories
Protein
(grams)
Carbohydrate
(grams)
Fat
(grams)
Vitamin C*
(mg)
Vitamin E
(mg)
Vitamin A
(RE)

Placebo
Pre
2554±239
153±18

Placebo
Day 14
2386±202
142±18

Placebo
Day 28
2519±330
129±12

Supplement
Pre
2624±214
123±14

Supplement
Day 14
2464±231
120±15

Supplement
Day 28
2519±227
108±13

261±30

270±26

270±34

294±37

259±32

266±36

108±12

83±10

105±21

110±14

87±7

106±19

96±19

98±26

86±16

32±8

64±20

71±21

4±1

6±2

5±2

3±1

4±1

5±2

6944±3363

5440±2165 4228±845

4478±1624

5485±2198 7786±3068

Data are mean±SEM.
* Condition effect for vitamin C (p=0.02).
No other differences of statistical significance noted (p>0.05).
Note: Values are for the 48-hour period immediately preceding each test day.
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Table 3. Resting heart rate and blood pressure of men assigned to placebo or supplement
Variable

Placebo
Pre

HR (bpm)
60.9±2.9
SBP (mm Hg) 113.0±2.2
DBP (mm Hg) 70.3±1.2

Placebo
Day 14

Placebo
Day 28

Supplement
Pre

Supplement Supplement
Day 14
Day 28

62.2±2.6
107.8±3.1
70.5±3.6

61.1±2.8
110.2±2.6
67.9±2.7

65.6±2.0
108.8±2.8
66.5±2.5

65.3±2.3
109.1±3.2
67.6±2.2

65.1±3.0
112.6±2.3
71.2±2.4

Data are mean±SEM.
No differences of statistical significance noted (p>0.05).
Note: HR=Heart Rate; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure

3.3 Subject’s perceived feelings and blood analyses
No interaction effect was noted (p>0.05) for subjects’ perceived feelings associated with
use of the placebo and supplement (Table 4). However, a condition effect was noted for
Muscle Strength (p=0.05) and Physical Appearance (p=0.01), with values higher for
supplement compared to placebo. In addition, a day effect was noted for Muscle
Endurance (p=0.04) and Sleep Quality (p=0.005), with day 28 higher than base line.
Blood testosterone and estradiol data are presented in Table 5. No effects were noted for
total or free testosterone, or for estradiol (p>0.05).
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Table 4. Perceived feelings of men assigned to placebo or supplement
Variable
Alertness
Energy Levels
Vitality
Libido
Workout
Effectiveness
Muscle Strength*
Muscle Endurance**
Sleep Quality**
Mental Outlook &
Mood
Physical Appearance
*

Placebo
Pre
3.4±0.2
3.4±0.2
3.5±0.2
3.6±0.2
3.9±0.3

Placebo
Day 14
3.5±0.3
3.6±0.2
3.6±0.3
3.8±0.3
3.8±0.1

Placebo
Day 28
3.8±0.1
3.7±0.1
3.9±0.2
4.2±0.2
3.9±0.1

Supplement
Pre
3.8±0.2
3.6±0.3
3.8±0.2
3.8±0.3
3.7±0.3

Supplement
Day 14
3.8±0.2
3.8±0.1
3.8±0.1
3.9±0.2
4.3±0.3

Supplement
Day 28
3.8±0.2
3.8±0.2
4.0±0.2
4.2±0.2
4.1±0.2

3.5±0.3
3.5±0.2
3.1±0.3
4.2±0.3

3.7±0.1
3.8±0.1
3.2±0.2
3.8±0.2

3.7±0.1
3.8±0.2
3.4±0.3
3.8±0.2

3.5±0.2
3.4±0.2
2.8±0.2
3.9±0.2

4.2±0.2
4.0±0.2
3.7±0.2
3.9±0.2

4.1±0.2
4.0±0.2
4.0±0.2
4.3±0.1

3.6±0.2

3.7±0.2

3.7±0.1

3.8±0.2

4.1±0.2

4.1±0.2

Data are mean±SEM.
* Condition effect for Muscle Strength (p=0.05) and Physical Appearance (p=0.01).
** Day effect for Muscle Endurance (p=0.04) and Sleep Quality
(p=0.005); Day 28 > Pre. No other differences of statistical significance
noted (p>0.05).
Note: Using a rating of 1-5, with 1 representing the lowest rating and 5
representing the highest rating, subjects were asked to rate each variable in the
above table, with consideration of how they felt during the prior two weeks.

Table 5. Biochemical data of men assigned to placebo or supplement
Variable

Placebo
Pre

Placebo
Day 14

Placebo
Day 28

Supplement
Pre

Supplement
Day 14

Supplement
Day 28

Testosterone
5.3±1.2
-1
Total (ng∙mL )

5.3±1.1

5.3±1.2

6.2±2.2

5.5±1.3

5.1±1.3

Testosterone
Free (pg∙mL-1)

10.6±1.7

10.6±1.7

11.2±2.0

11.4±1.8

10.2±0.9

9.7±0.9

Estradiol
(pg∙mL-1)

14.7±5.1

15.4±4.8

14.4±5.0

29.0±14.6

26.0±10.6

22.5±8.2

Data are mean±SEM.
No differences of statistical significance noted (p>0.05).
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CHAPTER 4
Discussion
We examined the effects of DAA administration on serum total and free testosterone, in
addition to estradiol, in healthy men. We hypothesized that treatment with DAA would
lead to an increase in testosterone of similar or greater magnitude than has previously
been reported in the lone study of Topo and colleagues (XVII). This was based primarily
on the longer time course of treatment in the present study (28 days versus 12 days), and
the fact that Topo and colleagues noted a progressive increase in testosterone
concentrations with time. The present study also extended the literature pertaining to
DAA supplementation, as we included the measurement of serum estradiol, something
that had not been studied at the time that the present investigation was designed.
Our biochemical analysis indicated no increase in free or total testosterone from baseline,
following DAA supplementation (Table 5). These findings refute those of Topo et al.
who noted an approximate 42% increase in total testosterone following just 12 days of
DAA supplementation in young (aged 27-37 years) and healthy men (XVII).
Interestingly, this finding was observed in 20 out of 23 subjects in the study by Topo and
coworkers. However, Willoughby and Leutholtz recently reported that the same dosage
of DAA for a 28 day period failed to yield an increase in total or free testosterone in
young (aged 18-23 years) and healthy men (XVIII). It should be noted that DAA
treatment was compared to a placebo and provided in conjunction with a resistance
training program. These results of Willoughby and Leutholtz (XVIII) parallel those of
the present investigation and suggest that DAA does not increase serum total or free
testosterone in young and healthy men. The slight discrepancy in the age of subjects
11

between the three studies (Topo et al 27 to 37 years, Willoughby and Leutholtz 18-23
years, and the present study 19-39 years) may explain conflicting findings (XVII,
XVIII). Basal testosterone levels must be taken into account as well: Topo 4.55 ± 0.55
(ng/ml),Willoughby and Leutholtz 7.78 ± 1.24 (ng/ml), the present study, treatment
group 6.2±2.2 (ng/ml) and placebo group 5.3±1.2 (ng/ml) (XVII,XVIII). With only three
published studies to date to evaluate the impact of DAA supplementation to stimulate
testosterone production, more work is needed in this area in order to more fully elucidate
the role of DAA to stimulate testosterone production in otherwise healthy men with
normal testosterone values.
In prior literature, DAA has been shown to increase the synthesis and release of
testosterone in animals (VIIXIVVIIIV, V, VII, XIV, XVII). It appears to do this by
stimulating the hypothalamic-pituitary-gonadal (HPG) tract to synthesize and release
hormones. In a study using adult male rats (XVII), three groups of 10 animals each were
treated for 12 days with a solution containing 20mM of DAA (XVII). After 12 days of
treatment, testosterone increased significantly, from a baseline mean value of 5.1 ± 0.8
(ng/ml) to 10.4 ±1.2 (ng/ml), reported as mean ± SEM (XVII). In a study by D’Aniello et
al (XIV), injections were administered to adult male rats and blood samples were
collected at five hours post injection. Testosterone and LH increased from baseline 3-fold
and 1.6-fold, respectively (IV). It has also been demonstrated that DAA acts to stimulate
N-Methyl-D-aspartic acid (NMDA) synthesis, leading to a small hormonal release from
the hypothalamus (VII).
Within in vitro experiments, the rat pituitary has been used to study LH levels
after incubation in a solution containing DAA (XVII). After incubating the pituitary in a
solution of 0.1mM DAA, LH increased 1.8-fold from baseline. LH also significantly
12

increased in a solution of 1.0 mM, but the increase was not proportionate to the amount
of DAA in the solution. Solutions containing Leydig cells have been used to study the
effect of DAA on testosterone levels (XIV, XVII, XIV). For example, when purified
Leydig cells were incubated at increasing times, a time-dependent effect is observed,
with the highest levels of testosterone observed at six hours following incubation, with
values decreasing significantly after 21 hours of constant incubation (XIV). This finding
suggests that DAA may need to be introduced regularly (daily) for optimal effects.
The body naturally controls the release of hormones in the hypothalmus-antierior
pituitary-gonadal (HPG) tract by positive and negative feedback mechanisms which are
regulated by hormones such as LH and testosterone (XIII). Low blood testosterone
triggers the hypothalamus to release gonadotropin releasing hormone (GnRH), causing
release of LH from the anterior pituitary (XIII). An increase in testosterone causes a
negative feedback on the hypothalamus suppressing GnRH release (XVI,XIII,XVI).
Aging or a decline in endocrine functioning can result in the male testes producing
decreased levels of androgens, including testosterone (XII,XVIII). A widely accepted
mechanism of age-linked deterioration in the hypothalamic-anterior pituitary-testicular
axis is a decrease in LH secretory burst amplitude and frequency (XVII).
With the above in mind, it should be noted that our sample consisted of a group
of young men between the ages of 18-39 whose testosterone levels were in no way
considered to be low at baseline (Table 5); normal range ~ 290-925 ng/dl (XV). Men in
this age range with a well working HPG tract may not experience an effect form DAA
supplementation because these men are producing testosterone levels in the mid-range of
normal, which may be minimizing extra GnRH release on all levels of the HPG tract
(XV). It is possible that the slight discrepancy in the age of subjects between the three
13

studies in which DAA has been administered could be responsible for the conflicting
findings. For example, subjects in the Topo et al study ranged in age from 27VII to
37VII years, as compared to the present study (18-39 years) and that of Willoughby and
Leutholtz (18-23 years) (XVII,XVIII). The collective body of literature, inclusive of the
above mentioned work and the work involving animal models, leads us to suggest that
DAA may be more beneficial for older men, in particular those with depressed basal
levels of testosterone. Moreover, the dosage of DAA may need to be greater than 3
grams daily in order to realize an effect on testosterone elevation. More work is needed
to test these hypotheses.
Aside from the focus on testosterone, it has been reported in animal studies that
DAA may lead to increased estradiol—a result of increased aromatase activity and the
conversion of testosterone to estradiol (I,X,XI). To our knowledge, at the time of
designing the present investigation, this finding had only been observed using animal
models. Since that time, a lack of estradiol increase following DAA supplementation has
been reported by Willoughby and Leutholtz (XVIII). Our findings agree with those of the
aforementioned authors, noting no increase in estradiol with DAA supplementation for a
period of 28 days. In fact, in both our study and the study of Willoughby and Leutholtz
(XVIII), values decreased slightly over the course of treatment. It should be noted that

two of the 12 subjects in the present study who were assigned to the DAA condition had
very high levels of estradiol at baseline, influencing the group mean. The fact that
estradiol was lower following treatment with DAA eliminates the possibility that DAA
initially promoted an increase in testosterone, only to have this increase abolished by a
rapid conversion toward estradiol. Our findings coupled with those of Willoughby
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and Leutholtz (XVIII) indicated that DAA has no impact on either testosterone or
estradiol in a sample of young and healthy men.
Although not a primary outcome measure in the present study, we noted small
improvements in subjective feelings of muscle strength in subjects assigned to the
supplement. While it is possible that DAA treatment was responsible for this enhanced
feeling of muscle strength, it should be noted that the supplement also contained
sodium nitrate, which resulted in a significant increase in plasma nitrate/nitrite levels-a surrogate marker of nitric oxide (NO) levels. Nitric oxide plays a role in regulation
of vasodilation, blood flow, and mitochondrial oxidative phosphorylation (II,III).
Related to physical performance, the increase in NO has been reported to increase time
to exhaustion during exercise (II,III,IX). It is possible that subjects reported feeling
greater muscle strength (and to some extent, muscle endurance) due to the nitrate
ingestion within the supplement. Additional work including DAA alone would be
needed to confirm the independent role of DAA on subjective feelings of muscle
strength and endurance.
In conclusion, we report that DAA supplementation for a 28 day period does not
increase serum total or free testosterone in young, healthy men. Moreover, there is no
impact on serum estradiol concentrations. These data agree with the very recent findings
of Willoughby and Leutholtz (XVIII), yet refute those of Topo and colleagues (XVII).
Additional studies are needed, using both young and older men (with either normal or low
testosterone levels), to determine the potential influence of DAA on testosterone
concentrations.
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Such work should consider the inclusion of physical performance testing, in an
attempt to determine if any noted increase in testosterone is related to an improvement in
physical performance.
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CHAPTER 6
Extended Literature Review
6.1 Introduction
D-aspartic acid (DAA) is an endogenous amino acid found in vertebrates and nonvertebrates that plays a role in the nervous, endocrine, and neuroendocrine system (XVII).
It is produced in the body through the conversion of L-aspartic acid by an enzyme
referred to as aspartate racemase (XVII). Recently DAA has become very popular as a
dietary supplement, particularly among athletic men. This is largely fueled by one human
study demonstrating an increase in blood testosterone concentrations following daily
supplementation with DAA over the course of a 12- day period (LXXVI). While the rise in
testosterone is the finding of most interest to male athletes, DAA may have other healthrelated implications worth noting. For example, scientists have begun to study the role of
DAA within the nervous system and neuroendocrine system. While the mechanisms are
not yet well understood, DAA can be converted into N-methyl-DAA receptors (NMDA
receptors), which are a crucial part of the memory/learning process (VI). Therefore it is
hypothesized that DAA may play a role in improving certain diseases such as
Alzheimer’s (VI,VIII) . In addition, DAA has been shown to play a role in the male
reproductive system via its involvement in the synthesis and release of sex hormones
(VIIIV,VII), namely testosterone.

6.2 What is Testosterone?
Testosterone is an androgen that plays a particularly important role in the male body, by
promoting muscle hypertrophy, vitality, and germ cell development (XXXV, LXIII). Leydig
cells in the testes are stimulated to produce testosterone by luteinizing hormone (LH)
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(XIV, XVI, XXXIV). Follicle stimulating hormone (FSH) also contributes to testosterone

production by increasing the number of LH receptors in the Leydig cell (LXXIV).
Synthesis and release of testosterone is regulated by the hypothalamic-pituitarytesticular axis. When testosterone is low, the hypothalamus releases gonadotropin
releasing hormone (GnRH), which in turn causes the anterior pituitary to release LH in
a pulsatile manner (LVI), leading to an increase in testosterone. Testosterone
concentrations provide negative feedback to the hypothalamus decreasing or stopping
GnRH and other gonadotropin-derived hormone release (LVI, LXXIV).
The first step in testosterone biosynthesis is the conversion of cholesterol to
pregnenolone. This occurs in the mitochondria of the Leydig cell and is catalyzed by the
cytochrome P450 enzyme, cholesterol side-chain cleavage (P450scc) (LXIII). The
conversion of cholesterol by P450scc yields pregnenolone, a potential precursor to
testosterone (LXIII, LXXII). In short, progesterone is transported to the smooth endoplasmic
reticulum where it is converted to androstenediione by P450 cytochrome 17-alphahydroxylase (P450c17). Finally, testosterone is derived from androstenediione via 17beta-hydroxysteroid dehydrogenase (LXIII). There are numerous intermediate enzymes and
hormones involved in this process, meaning there is not just one enzyme pathway leading
to testosterone production (IV,XXI,XXVIII,XXI,XXXVII,LXVI,LXVII,LXVIII,LXXVII,LXXVIII). The
enzyme and hormone intermediates involved are most likely concentration dependent
(LXIII). Species may also play a role. For instance, the pathway that rats and dogs use for

testosterone biosynthesis differs from each other, just as they differ from the pathway used
by humans (LXIII).
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6.3 Role of Testosterone in Human Physiology
Muscle Growth The process of muscle hypertrophy is regulated by multiple hormonal
and nutritional mechanisms (XXXVI, LXXI). Testosterone is involved in hypertrophy of type I
and Type II muscle fibers (LXXI). Furthermore, supplementation of testosterone in healthy
hypo- gonadal men has been shown to not only cause hypertrophy of both muscle fiber
types, but also to increase fat-free mass (VII). Evidence indicates that testosterone
promotes muscle anabolism by stimulating protein synthesis, decreasing muscle protein
breakdown, and increasing amino acid recycling by skeletal muscle (VII,LXX , LXXIV).

Testosterone and Overall Wellbeing Testosterone is linked to cognitive, emotional, and
physical well-being in all ages, genders, and fitness levels (L,LI). Aging or a decline in
endocrine functioning can result in the male testis producing decreased levels of
androgens, including testosterone. A widely accepted mechanism of age-linked
deterioration in the hypothalamic- anterior pituitary-testicular axis is a decrease in LH
secretory burst amplitude and frequency (LXXIV). Low testosterone is linked to
depression, nervousness, insomnia, fatigue, decreased libido, and cognitive deficits (LI).
However, current data suggest that testosterone supplementation, in an attempt to bring
testosterone back to acceptable levels, may combat these characteristics linked to
androgen deficiency (XXXVIII). Additional conditions such as Alzheimer’s disease,
diabetes type II, hypogonadism, and acute post-operative frailty have been associated
with low testosterone levels in men (VI,XXXVIII,L,LII,LXXX). While testosterone naturally
decreases in older men, it may decline to an even greater extent during times of great
illness. For example, men undergoing cardiac-revascularization have shown post33

operational testosterone levels of less than 200 ng/dl (LII). It is proposed that, in this
population, testosterone supplementation would greatly benefit physical recovery and
performance (LII,LXXIII). This may extend beyond recovery from cardiac procedures. The
literature shows that an increase in blood serum testosterone levels, due to a testosterone
supplementation intervention, will concomitantly increase cognitive abilities, particularly
visual-spatial abilities in persons with Alzheimer’s disease (LXXV).

6.4 Methods of Increasing Testosterone
Exercise Testosterone can be increased by multiple means, not just through exogenous
supplementation. Acute resistance exercise increases serum total and free testosterone in
both younger and older men (XXXVI). For example, untrained men were taken through a
heavy exercise training routine three times, with a 48-hour rest period between each
exercise bout. An increase in serum testosterone was observed immediately and 30
minutes after each training session (LXXXVIII). Similar studies have been conducted with
young and older untrained men taken through long-term training programs. While
baseline testosterone levels remained the same, acute increase in testosterone were
observed (I,LXI).
Weight loss has also shown to increase male reproductive hormones. For
example, a 14- week study involving weight loss induced by both diet and exercise
noted that BMI was negatively associated with testosterone, while it was positively
associated with estradiol (XXVII). Percent weight loss during the program was associated
with a percent increase in testosterone. On the other hand, weight loss did not decrease
serum estradiol levels. Men in this study were severely obese at the beginning of the
intervention and remained obese by the conclusion of the study (XXVII), so it is unknown
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if similar results would be observed in those who are not obese.

Medications A common form of increasing testosterone is through us of anabolicandrogenic steroid (AAS) use. AASs are derivatives of testosterone that promote
protein synthesis, muscle growth, and improved athletic performance (XL). Examples of
these drugs are testosterone undecanoate and testosterone enthate (LIV). They are used
by are range of populations, ranging from competitive athletes to bodybuilders and
recreational athletes looking to improve their overall physiques. However, physicians
may prescribe them to men with low endogenous testosterone levels, as well as a
treatment for a number of disorders such as delayed puberty or hypogonadism. In a
recent observational study, long term AAS users showed less fat mass and higher lean
mass than non-AAS using athletes (LXII). Commonly reported effects of AAS use
include an increase in fat free mass, a decrease in fat mass, and an increase in libido
(XL,LIV,LXII).

While there are many benefits to testosterone supplementation, many adverse
effects also have been reported. Ingestion of AASs can lead to reproductive disorders,
liver toxicity, and cardiovascular problems linked to high LDL and low HDL (LIV,LXII).
Moreover, testosterone can be delivered by injection, nasal spray, skin patch, or by skin
cream application. Some of these methods come with the risk of pain or discomfort to the
patient (XXXVIII,LIII).

Nutritional Interventions: Alteration in Macronutrient mix Macronutrient ratios in
the diet, as well as other dietary considerations such as alcohol consumption, may alter
testosterone levels (XXIII, XXIX). Literature indicates that diets high in fat result in higher
serum testosterone levels (XIX, XXIX). In particular, men who maintain a total daily caloric
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consumption of 40 percent fat, with a high percentage of saturated fat, show higher
serum testosterone levels compared to those who have a low fat diet of about 25 percent
fat (XXIX). Testosterone concentrations in men consuming high carbohydrate/low protein
diets were greater compared to men consuming low carbohydrate/high protein diets (II).
However, in a study with male rabbits, manipulation of the carbohydrate/protein ratio
yielded no change in testosterone levels (XLIX).Acute resistance training has been shown
to increase testosterone post exercise (I,LXI,LXXIX, ), but ingestion of protein before or
after exercise has been shown to diminish the increase in serum testosterone usually
observed immediately after heavy resistance training (IX, XXXIV,XLIII). A recent study
showed that 15g of whey protein prevented the increase in free and serum testosterone in
moderately-trained older men (XXXVI). Similar findings have been seen in young men
supplementing protein and carbohydrate either pre or post workout (XXXV, XXXVI).
However, the lack of increase in serum testosterone may be due to the uptake of
testosterone into the skeletal muscle fibers post workout, possibly due to the need to
promote increased protein synthesis in conjunction with protein supplementation (IX,
XXXVI).

Nutritional Interventions: Alterations in Micronutrients Alteration in micronutrient
intake may also effect endogenous testosterone production (LXVV,LX,LXV). In overweight
men with vitamin D deficiency, one year of vitamin D administration (a dose of > 3,000
IU) significantly increased testosterone production (LIV). These data suggests two things:
1) there is a link between vitamin D and testosterone level and 2) the male reproductive
tissue is a target area for vitamin D activity (LXIV). The vitamin D receptor (VDR), as well
as key enzymes for vitamin D metabolism, has been observed at high levels in male
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reproductive tissue, including Leydig cells (LXIV). These data, along with data suggesting
that vitamin D deficiency may contribute to hypogonadism, indicate that vitamin D plays
a role in the male reproductive system and hormone production (LXIV).
Trace minerals may also play a role in testosterone production. Decreased
production of gonadotropic hormones, such as LH, has been identified as the main
reason for low testosterone levels in men with zinc deficiency (XLII). Zinc has also shown
to play a role in male reproductive physiology in adults and children as shown in
population suffering from pathological conditions causing zinc deficiency (XLII, LXV).
Zinc supplementation in older men who are zinc deficient may increase serum
testosterone concentrations (LXV). In contrast, young men with mild zinc deficiency
induced through dietary restriction showed a decrease in serum testosterone levels (LXV).
This evidence is further supported by studies with rat tissue, where zinc deficient rats
developed hypogonadism primarily caused by failure of the Leydig cell (LV). Therefore,
it can be speculated that mild zinc deficiency results in decreased serum testosterone
levels and zinc treatment would improve testosterone levels (LXV). However, this does
not necessarily mean that zinc supplementation in men with appropriate zinc levels
affects testosterone production (XLII).

6.5 What is D Aspartic Acid (DAA)?
DAA Described All amino acids, with the exception of glycine, can exist as one of two
stereoisomers (XV, XXXIX). These forms are known as L-forms and D-forms. L-amino
acids are naturally occurring compounds in the body. L-aspartic acid in particular, is
oxidized by an enzyme called aspartate racemase, and converted to DAA through a series
of reactions (XV, XLI). In addition to these chemical considerations, DAA is oxidized by
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DAA Oxidase (X,XVIII). DAA concentration can be measured as wet weight in nmol/g or
as a proportion referred to as D%. This is the proportion of D-amino acid in total amino
acid [D-form/ (D-form + L-form) * 100%] (XXXIII). DAA is found in a wide variety of
mammalian tissue, particularly the central nervous system, neuroendocrine, and
endocrine system (X,XI,XIII,XX,XIV,XLVIII,LIX,LXIX), and was first reported by Dunlop and
colleagues in 1986 to exist in humans (XX).

Nervous System Animal studies support DAA as a promoter of proteins involved in
nervous system development and as an active neurotransmitter or neuromodulator at
synapses (XV). In chickens and rats, DAA is one of the many factors involved in the
development of the central nervous system before and for a short period after birth (XX,LIX).
Research focusing on the role of DAA in vision showed that, when left in the dark, DAA
levels in animal retina decrease. However, when the animal is re-introduced to light DAA
levels return to normal (XVII). In rat retina, DAA has been observed during the early stages
of development. The highest concentrations are reached seven days (D% 29) after birth,
with most of the DAA collecting in the nerve fibers (XX,LIX). It is clear that, in many
animals, DAA is one of the underlying factors of central nervous system development
during the fetal stages and the first few days of life.
Additionally, in humans, DAA is a biological precursor to N-methyl-DAA
receptors (NMDA). DAA also stimulates NMDA receptor activity by binding to L-glut
receptors leading to a hormone release from the hypothalamus. It has been established
that NMDA receptors take part in central nervous system functioning, such as
stimulation of the hypothalamus (XV) and long-term potentiation, a component of the
learning and memory process. Furthermore, in rats, a loss of NMDA receptors causes a
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marked reduction in memory and decreased acquisition and retention of visualdiscrimination tasks (XIII). Therefore, it is hypothesized that DAA may play a role in
certain diseases such as Alzheimer’s (XIII, XV,XXII,XXIV). Postmortem human brain samples
taken from persons with Alzheimer’s showed a significant reduction in free DAA
compared to levels of aged matched controls (XIII). This suggests that lower DAA levels
could contribute to lower NMDA receptor levels, and contributing to memory loss in
persons with Alzheimer’s (XIII). Improper functioning NMDA receptor
neurotransmission has been linked to other mental illnesses such as depression and
schizophrenia (XXIV) adding therapeutic potential of DAA.

Neuroendocrine System As with nerve tissue, DAA is also observed in the endocrine
system. Fleeting levels of DAA have been observed in the adrenal gland of newborn rats.
At three weeks of age, DAA concentration increases but is quickly followed by a
dramatic decline (XXXIII). In contrast, DAA levels in other neuroendocrine and endocrine
tissue such as the pineal gland, pituitary gland, and testis throughout development
(XXXIII). DAA concentrations in the pineal gland of rats are very high (D% of 33), and are

regional with the majority of DAA being found on the distal portion of the gland
(XXX,XXXIII,LXIX). The pituitary gland consists of the anterior, posterior, and intermediate

lobes, but DAA is not observed in the intermediate lobe. It is found in the anterior lobe
at seven times (140 nmol/g) higher concentration than the posterior lobe (20 nmol/g)
(XLVII). Large amounts of DAA are found in the rat testis as well (220 nmol/g) (LXIX).

6.6 Mechanism by Which DAA Promotes the Synthesis of Testosterone and LH
The enzyme aspartate racemase, which converts L-aspartic acid to DAA, has
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recently been shown to be present in high concentrations in elongated spermatids in
mouse testis (XLI). This suggests the ability for spermatids to synthesize DAA
independently through the conversion of existing L-aspartic acid to DAA. Evidence
reports that the synthesized DAA can then be secreted from the seminiferous tubules and
acts on the Leydig cells to promote testosterone synthesis (XII). This effect has been
shown to be specific for DAA, as no increase in testosterone synthesis is observed after
treatment with L-aspartic acid, L- glutamic acid, or D- glutamic acid (LVIII). It appears that
DAA is taken up by L-glut transporter and the amount of DAA taken up by the cell is
correlated with the amount of testosterone produced (XXXIX).
Testosterone synthesis is initiated by the transport of cholesterol into the
mitochondria. Delivery of cholesterol into the mitochondria is the rate-limiting step in
testosterone synthesis (LVII, LXIII). The key regulatory protein that facilitates this delivery
is the steroidogenic acute regulatory protein (StAR). Addition of DAA to cultures of
Leydig cells increases StAR protein levels (LVII). Thus, it would appear that DAA
increases testosterone production by enhancing StAR protein gene expression inside
the Leydig cell. Through this mechanism, DAA is produced in germ cells, and may
attribute to testosterone production and germ cell proliferation in the testis (LVII). DAA
can be secreted and absorbed through a number of different pathways; however, it is
clear that the Glut-4 transporter is a potential factor in the transportation of DAA into
the cell (XXXIX).

cAMP and cGMP Second Messenger System D- aspartic acid is involved in the release
and synthesis of LH and testosterone through a second messenger system involving
cAMP and cGMP (LXXVI). This is predominantly seen in anterior pituitary tissue and
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Leydig cells. The pituitary gland receives its instructions from the hypothalamus via the
hypophyseal pituitary portal system (a vascular link predominantly composed of
neurosecretory cells). The anterior pituitary produces LH, which stimulates testosterone
synthesis and secretion in interstitial Leydig cells. When adult rats were given injections
of DAA, it accumulated in the anterior pituitary gland and Leydig cells, leading to an
increase in LH and testosterone (XI). In a pituitary gland incubated with a solution of
DAA, LH and cGMP synthesis increased (XI), indicating that the release of LH occurs in
the presence of cGMP. When similarly incubating Leydig cells with DAA, Leydig cells
were stimulated to synthesize testosterone (LXXVI), with a concurrent increase in cAMP
(LXXVI). Interestingly, when testosterone levels in the Leydig cells drop below sufficient

levels, germ cell apoptosis accelerates (XXV), leading to a negative feedback mechanism in
the testes that increases DAA levels. This in turn increases the rate of testosterone
synthesis in the Leydig cells, further indicating the role of DAA in the synthesis of
testosterone (XXXIX,LVIII,LXXVI).

6.7 DAA Use in Animal Studies
In Vivo In vivo animal studies have been done to investigate the effect of DAA
administration on serum testosterone levels. In a study using adult male rats (LXXVI), three
groups of 10 animals each were treated for 12 days. Group one drank a solution of 3.12
g/10ml DAA for twelve days, Group two drank a solution of 3.12 g/10ml DAA for twelve
days then drank tap water for 3, and Group 3 drank a placebo solution of NaCl for twelve
days. After 12 days of treatment, testosterone increased significantly, from a base mean
value of 5.1 ± 0.8 (ng/ml) to10.4 ±1.2 (ng/ml) reported as mean ± SEM (LXXVI). Other in
vivo experiments have used i.p. injections of DAA to demonstrate its ability to increase
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testosterone and LH (XI, XIV). In a study by D’Aniello et al (XI), injections were
administered and blood sample collected at five hours post injection. Testosterone and LH
increased from baseline 3-fold and 1.6-fold, respectively (XI). It has also been
demonstrated that DAA acts in vivo by stimulating NMDA synthesis. This increased level
of NMDA leads to a small hormonal release from the hypothalamus (XVI).

In Vitro In vitro experiments primarily use pituitary and Leydig tissue, in which DAA
accumulates at the greatest concentrations (LVIII,LXXVI). The rat pituitary has been used to
study LH and cGMP levels after incubation in a solution containing DAA (LXXVI). After
incubating the pituitary in a solution of 0.1mM DAA, LH increases 1.8-fold from
baseline. LH also significantly increased in a solution of 1.0 mM, but the increase was
not proportionate to the amount of DAA in the solution. Additionally, an increase in
cGMP was seen with the increase in LH, but the increase was also not proportionate to
the amount of DAA in the solution. Therefore, a ceiling concentration of DAA may exist
in vitro. Both solutions were incubated for 60 minutes. After incubation the tissue was
divided into two portions to be centrifuged separately. After 5 minutes of being
centrifuged, the supernatant was collected and used to determine LH concentration
(LVIII,LXXVI).

Solutions containing Leydig cells have been used to observe DAA’s effect on
testosterone and cAMP levels (LVIII,LXXVI). In one method (LXXVI), solutions of 0.1 mM
and 1.0 mM of DAA were prepared and added to a Leydig cell suspension. After 60
minutes of incubation the solution was divided into two portions, one for testosterone
and a second portion for cAMP measurements (LXXVI). Testosterone significantly
increased 2.4 fold and 2.94 fold from baseline in solutions of 0.1 mM and 1.0 mM DAA
42

respectively. Concentration of cAMP increased 3.1 fold when incubated in a solution of
0.1 mM and 5.25 fold when incubated in 1.0 mM DAA. This indicates that stimulation
of the Leydig is accompanied by an increase in cAMP (LVIII,LXXI). When purified Leydig
cells are incubated at increasing times a time-dependent effect is seen. Highest levels of
testosterone were observed at six hours. A sharp decline in testosterone was then
observed in the culture incubated at 21 hours (LVIII). This suggests that DAA may need to
be introduced regularly (daily) for optimal effects.

6.8 Aromatase Activity and Estradiol
In vitro experiments with boar and lizard tissue have indicated that the addition of DAA
induces an increase in P450 aromatase activity, which is a key enzyme in the conversion
of testosterone to estradiol (III,XLIV,XLV). Aromatase belongs to the cytochrome P450
super-family and is expressed in tissue such as the ovaries, adipose tissue, the brain, and
the testis (LVI). Some species (i.e., boars), are known to have naturally up-regulated
testicular aromatase (LXIII). Increased estrogen in men is associated with multiple
undesirable effects such as gynecomastia, increased risk of stroke, and infertility (XXXII).
However, it is unclear if oral DAA ingestion would promote undesirable levels of
estradiol production in humans.
Aromatase activity and estradiol production should not be generalized as a negative
action in men. In aromatase-deficient men, little conversion to estrogen takes place
(VIII,LVI). This leads to increased gonadotropin hormone production that in turn may cause

macro-orchidism (XXVI). This is reversed with estrogen replacement therapy. P450
aromatase deficiency may induce harmful effects in adolescent males because increased
testosterone levels without estrogen results in skeletal maturation lacking epiphyseal
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fusion (VIII,XXVI). This supports estrogen’s essential role in pubertal growth in young men
(LVI). Furthermore, it was also reported that men with estrogen deficiency or resistance

have severe osteopenia (LVI). In young men with P450 aromatase deficiency, estrogen
replacement therapy can prevent bone loss and even reverse osteoporosis. Lipid and
glucose metabolism are also negatively affected by low estrogen levels due to P450
aromatase deficiency (LVI). An interesting case report followed a patient with aromatase
deficiency highlighting the impact aromatase deficiency has on estradiol and testosterone
(VIII). The patient had normal levels of serum testosterone, slightly elevated LH levels,

and undetectable levels of estradiol. The patient was treated with estradiol twice weekly.
After six months of treatment, bone pain, which had been a chronic ailment, was
completely alleviated. At the beginning of treatment, the patient still had open epiphyseal
plates. After nine months of therapy, epiphyseal closure was observed along with an
increase in bone mineral density. Treatment did not induce any negative side effects such
as gynecomastia and sexual dysfunction (VIII). The above cases highlight the importance
of adequate estrogen levels in men.
6.9 Effect of DAA Supplementation in Humans
Fertility DAA is present in human seminal plasma and in spermatozoa in high
concentrations (XVII). The ratio of DAA to L-aspartic acid is higher in isolated
spermatozoa (28.5%) than in seminal fluid (15.5%) (XVII). This means that spermatozoa
may have the ability to synthesize DAA, or possibly the ability to take DAA from the
seminal fluid (XVII). The occurrence of DAA in the testis may come from the conversion
of L-aspartic acid to DAA by aspartate racemase. DAA levels are known to be higher
in normospermic males than non- normospermic males (XVII). Because of this it is
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hypothesized that DAA could play a role in sperm cell synthesis and maturation (XVII).

Testosterone, LH, and Estrogen In a study by Topo et al., two groups of healthy young
men between the ages of 27-37 were observed for 12 days. Group one, the experiment
group, consisted of 23 men while group two, the control group, consisted of 20 men.
Every day at breakfast, for 12 days, the experiment group consumed a solution containing
3.12 g DAA with vitamins B6, folic acid, and B12. The control group followed the same
protocol but received a solution of NaCl and vitamins B6, folic acid, and B12. Blood
samples were taken pre, mid, and post the 12-day intervention, as well as three days posttreatment. Blood was collected for the measure of serum hormones, between the hours of
9:30-10:30 am to account for serum hormone oscillations (XVII, LXVI). Twenty of the 23
subjects receiving DAA experienced significant increases in LH compared to mean
baseline values. A 33% increase from base levels of 4.2±0.5 mIU/mL to 5.6±0.9 mIU/mL
was reported as mean ± SEM. No increase in LH was observed in the placebo group,
authenticating DAA’s treatment effect. The effect of DAA was time dependent, in that
LH levels reached their peak at twelve days of treatment. Twenty of the 23 subjects also
experienced an increase in serum testosterone levels. Serum testosterone increased from a
mean base value of 4.5±0.6 ng/mL to 6.4±0.8 ng/Ml. This 42% increase in serum
testosterone was also time dependent (XVII,LXVI). Recently, Willoughby and Leutholtz
(LXXIX) reported that the same dosage of DAA for a 28 day period failed to yield an
increase in total or free testosterone in young (aged 18-23 years) and healthy men
(LXXIX). It should be noted that DAA treatment was compared to a placebo and provided

in conjunction with a resistance training program (LXXIX). While the above findings are
interesting, future studies are needed to expand on the work of Topo and colleagues and
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Willoughby and Leutholtz(LXXVI,LXXIX). For example, varying dosages of DAA may be
considered. Including measures of physical performance, in addition to subjective
measures of vigor, health, and mood that are influenced by testosterone may be
considered in future research.

6.10 Conclusion
As stated by Lunenfeld et al (LI), the goal of testosterone treatment is to maintain a
standard quality of life and decrease the undesirable effects of testosterone deficiency (LI).
Recent evidence indicates that low levels of testosterone are linked to increased risk of
death (XLVI). Based on these findings, identifying methods of increasing testosterone
appear important, and DAA may be a viable and safe alternative to pharmaceutical
testosterone therapy. The ability of DAA to increase testosterone in human and animal
models supports this assertion (XV, 45, 58, LVI). With limited research done in humans,
further investigation is recommended. Specifically, studies are needed to assess the
impact of daily DAA administration on testosterone and associated parameters in normal,
otherwise healthy men.
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